Brand:SC
Model:Raloxifene HCL
MOQ:10 Gram
Send Inquiry
Email:alanyi@ycphar.com
Whatsapp:86-17301869715
Skype:iceliaoyi
| Product Name: | Raloxifene hydrochloride |
| Synonyms: | RALOXIFENE HCL;RALOXIFENE HYDROCHLORIDE;ly156758;,(6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidin;KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138 |
| CAS: | 82640-04-8 |
| MF: | C28H28ClNO4S |
| MW: | 510.04 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;Intracellular receptor;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceutical intermediate;API;Inhibitors |
| Usage: | It is used in the prevention of osteoporosis in postmenopausal women. |
Price: How many do you need? It depends on your amount of order for goods, the bigger the amount is, the more favorable the price.
Product: As a manufacturer, we can provide you the product directly, no middleman, so the price is more favorable.
Service: Good after-sales service is an important factor to ensure that we can long-term cooperation, We will provide customers with reasonable return service.
| Description: May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated. Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis. Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that oftamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer.1 Not indicated for reduction in the risk of noninvasive breast cancer. Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i.e., can cause developmental abnormalities such as birth defects. |
Recommended products:
| Test Raw Powder: Test CAS: 58-22-0 Test Undecanoate CAS: 5949-44-0 Test Acetate CAS: 1045-69-8 Test Propionate CAS: 57-85-2 Test Cypionate CAS:58-20-8 Test Isocaproate CAS:15262-86-9 Test phenylpropionate CAS:1255-49-8 Test Enanthate CAS: 315-37-7 Test Blend (Sustanon 250) Clostebol Acetate (Turinabol) CAS:855-19-6 FluoHalotestin CAS:1424-00-6 Test decanoate CAS:5721-91-5 |
Nandrlone Raw Powder:
| Nandrlone CAS:434-22-0 Nandrlone Decanoate (DECA) Deca-Durabolin CAS: 360-70-3 Nandrlone Phenylpropionate CAS:62-90-8 Nandrlone Propionate CAS:62-90-8 Nandrlone Cypionate CAS:601-63-8 Nandrlone Undecanoate CAS:862-89-598 Stanolone (Androstanolone) CAS:521-18-6 |
TrenboloneRaw Powder:
| Trblo Hexahydrobenzyl Carbonate Parabolan CAS: 23454-33-3 Trblo acetate Finaplix CAS:10161-34-9 Trblo enanthate CAS:10161-34-9 Trblo base CAS:10161-33-8 Trestolone CAS:3764-87-2 |
Anti-Estrogen:
Tamoxifen Citrate Novadex 54965-24-1
Clomifene citrate Serophene 50-41-9
Man Sex Enhancement:
Tadalafil 171596-29-5
Vardenafil 224785-91-5
Dapoxetine (Priligy) 119356-77-3
Best Sellers:
| T3 Na Liothyronine sodium Cytomel CAS: 55-06-1 CAS:434-07-1 Stanolone CAS:521-18-6 metandienone Dianabol CAS:72-63-9 Dextromethorphan Hydrobromide CAS:125-69-9 Methenolone Acetate CAS:434-05-9 1,3-Dimethylpentylamine CAS:105-41-9 Methenolone Enanthate CAS:303-42-4 Boldenone Undecylenate EQ CAS:13103-34-9 Drostanolone propionate CAS:521-12-0 Drostanolone Enanthate CAS:472-61-145 Yohimbine Hydrochloride CAS:65-19-0 1, 3 - dimethyleamine hydrochloride |
